{
  "query": "ALNY",
  "resolved": {
    "ticker": "ALNY",
    "cik": "0001178670",
    "title": "ALNYLAM PHARMACEUTICALS, INC."
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago",
      "entity": "Alnylam Pharmaceuticals",
      "ticker": "ALNY",
      "cik": "0001178670",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD",
        "nctId": "NCT05231785",
        "date": "2029-04-20"
      },
      "observed": {
        "event": "protocol updated 9 days ago",
        "nctId": "NCT05231785"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT05231785",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178670&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ALNYLAM PHARMACEUTICALS, INC. (ALNY) — PHASE1 protocol updated 9 days ago",
      "entity": "Alnylam Pharmaceuticals",
      "ticker": "ALNY",
      "cik": "0001178670",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease",
        "nctId": "NCT07214727",
        "date": "2030-03-06"
      },
      "observed": {
        "event": "protocol updated 9 days ago",
        "nctId": "NCT07214727"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07214727",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178670&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "ALNYLAM PHARMACEUTICALS, INC.",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-05-27",
        "accession": "0001628280-26-038499",
        "items": "5.02,5.07"
      },
      {
        "form": "8-K",
        "date": "2026-04-30",
        "accession": "0001628280-26-028601",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-03-04",
        "accession": "0001628280-26-014728",
        "items": "5.02"
      },
      {
        "form": "8-K",
        "date": "2026-02-12",
        "accession": "0001628280-26-007491",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-01-12",
        "accession": "0001628280-26-001755",
        "items": "2.02"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}